Domain Therapeutics

The IPCMS warmly thanks @DOMAINtx for its generous donation of laboratory materials, equipment and furniture, and assures that it will be used wisely!

Sarcoma merits #precisionmedicine all year-round! At @DOMAINtx, we take pride to be working with Pr Antoine Italiano, our leading partner in the @RHUCondor against Sarcoma! Thank you, Pr Italiano, for your commitment to developing novel #immunotherapies #sarcomaawarenessmonth

Read full article here: biotech-finances.com/domain-therape…

Success proven by science 👏 This is our firm belief! Our #precisionresearch & collaborations drive #pharma innovation. As leaders in #GPCR #immunooncology, we deliver cutting-edge cancer treatments. Thank you @Biotech_finance for this great article.

Best-in-class also works for choirs! 👏 Congratulations to 24 @DOMAINtx choristers for incredible performance at the solidarity concert organized by @LesBlousesRoses at the home for elderly. Music can help many of us find comfort and inspiration. #cancertreatment #immunooncology

Find out more: domaintherapeutics.com/domain-therape…

@DOMAINtx announces @EPOorg decision to grant a composition of matter #patent in > 15 European countries for its proprietary EP4 receptor antagonist program, including the candidate DT-9081, solidifying company's position as a leading #innovator in the field of #immunooncology

Read full article here: dna.fr/economie/2023/…

@DOMAINtx we believe in the untapped potential of #GPCRs to revolutionize #cancer treatment through #immunotherapy. Thank you @lndavid and @dnatweets for highlighting the #drugdiscovery potential of GPCRs in your recent article #immunooncology #drugdevelopment #precisionmedicine

🚲« Bike to work » June challenge is now over: 🎯@DOMAINtx is in the top 10 ➡️ 9th out of 243 🛣️ Distance covered: nearly 10,000 km ❔ approximately 2.53 tons of CO2 emissions avoided = trip from Paris to La Réunion! Congratulations to the Team! @CADR67 @strasbourg #Cancer

@DOMAINtx #ImmunotherapyMonth saw some major milestones. Our #pressday spotlighted our position as the "#GPCR company" in #immunooncology, unlocking the potential of GPCRs VS cancer. Nominations of DT-9045 & DT-7012 further confirmed our commitment to innovative #cancertreatments

@gazettelabo Merci Alicia et @gazettelabo. Nous sommes ravis d'avoir pu illustrer la valeur ajoutée du portefeuille de @DOMAINtx comme société leader dans les immunothérapies ciblant les #GPCR et annoncer la nomination du DT-7012 un anticorps anti-CCR8 qui entre en développement réglementaire

𝐂𝐎𝐍𝐅𝐄𝐑𝐄𝐍𝐂𝐄 𝐃𝐄 𝐏𝐑𝐄𝐒𝐒𝐄 - Invitée par @DOMAINtx, Alicia a pu assiter à la présentation de leurs activités et à l'annonce de l'identification d'un nouveau médicament-candidat. 💊 Elle a également visité leurs #laboratoires de #chimie et de #biologie. 🧪 #presse

To learn more on this great news, follow the link : domaintherapeutics.com/domain-therape…

Proud to announce the nomination of DT-7012, our best-in-class Treg-depleting CCR8 monoclonal #antibody strengthening our #pipeline of immunotherapies targeting #GPCR. With its potential & fast-track development we aim to optimize #immunotherapy effects. #precisionmedicine #IO

Hop on your bike for a greener planet! Kudos Team Domain for the effort on #auboulotavelo2023 & dedication to sustainability. Let's inspire others to join us on this eco-friendly journey. #sustainable #worklifebalance #Auboulotavelo @strasbourg @CADR67

@adMare_Bio @ThryvTrx Merci @adMare_Bio

👏 Félicitations à @ThryvTrx et @DOMAINtx, deux entreprises du portefeuille adMare, pour leurs formidables annonces de la semaine dernière ! Pour en savoir plus sur ces annonces, visitez ➡ admarebio.com/fr/actualites

June 5-8 I @DOMAINtx team will attend @BIOConvention 2023 in Boston. Reach out to learn more about our pipeline of best-in-class & first-in-class #GPCR-targeting assets in #immunooncology. #BIO2023 #DrugDevelopment #DrugDesign #PrecisionMedicine #Biotech

Happy to inaugurate our new HQ with friends & partners from our #innovation ecosystem. At @DOMAINtx we push the boundaries of science to unlock new possibilities in cancer while committing to #SustainableDevelopment. Our new building reflects that. Thank you all for your support.

Let’s race for #research against #sarcoma & rare types of #cancer in children & young adults, opportunity to make a donation to @BERGONIE33 & contribute to @RHUCondor combining #precisionmedicine & #immunotherapies for more efficient therapeutic management of sarcoma #patients

How can we increase cancer treatment success rate & cure more #patients?  Join @NeuvilleP at #Bioequity Europe 2023 for #presentation on our approach pioneering #GPCR #immunotherapies for #immunooncology: 15th of May / 10:10am / @TheCCD Dublin #investments @EBDgroup @BioCentury